Measles cases soar in Scotland as health chiefs issue vaccination plea
Measles is a highly contagious disease which is spread by coughs and sneezes. The virus can lead to pneumonia, brain swelling and death.
The number of measles cases has soared in Scotland with more infections recorded in the first five months of 2025 than the whole of last year.
Health chiefs have warned that this number could continue to rise as the infection sweeps across Europe. As of May, there were 26 confirmed cases in Scotland - compared to just 24 last year.
Although numbers remain small, health experts fear low vaccination rates in some areas could lead to an infection spike. Public Health Scotland (PHS) is encouraging the public to take up the offer of the Measles, Mumps and Rubella (MMR) vaccine.
It says having two doses of the jab is the best way to be fully protected against measles.
Dr Claire Cameron, Consultant in Health Protection at PHS said: 'As measles cases continue to increase across the world, we're working with health boards to ensure that as many people as possible are fully vaccinated with the MMR vaccine.
"Anyone who hasn't had two doses of the free MMR vaccine is encouraged to visit the NHS Inform website to find out how to arrange an appointment in their local health board area.
'We would also encourage those who are planning to travel anytime soon to ensure that you and your children are up to date with all your vaccinations before leaving the country.'
Measles is a highly contagious disease which is spread by coughs and sneezes.
The virus can lead to pneumonia, brain swelling and death.
It can affect people of any age if they have not been vaccinated.
Earlier this year, the World Health Organisation (WHO) reported that the number of cases in Europe was at its highest level for 25 years.
WHO regional director Henri Kluge called the surge in infections a "wake-up call".
He said: " Measles is back, and it's a wake-up call. Without high vaccination rates, there is no health security."
Uptake in Scotland remains high, with 90% of children having two doses by the age of six.
However, WHO recommends at least 95% of children are vaccinated.
The MMR vaccine protects against measles with the first dose offered to children between 12-13 months, and the second dose offered at three years 4 months.
If it's missed at these times, it can be given at any age.
PHS has warned a risk of infection remains in those who are not vaccinated or not fully vaccinated for their age.
Health care workers should also have two doses of MMR and are advised to speak to their employer or occupational health department if they haven't been fully vaccinated.
Further information on how to check if you or your child is fully protected can be found on MMR against measles | NHS inform.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
16 hours ago
- The Independent
Painful symptom of latest Covid variant identified
The NB.1.8.1, or "Nimbus," Covid variant is now nearly the most prevalent omicron lineage tracked by the CDC. A notable symptom associated with Nimbus is an incredibly painful "razor blade throat," though other symptoms are typical of Covid infection. Experts state that despite its rapid spread, the Nimbus variant does not appear to be more severe than previous strains. The variant's quick transmissibility is attributed to genetic mutations that allow it to bind easily to human cells. The World Health Organization has designated Nimbus as a "variant under monitoring" and considers the global public health risk to be low, with current vaccines expected to remain effective.
Daily Mirror
18 hours ago
- Daily Mirror
Gastroenteritis red flags after Real Madrid ace Mbappe misses game
The Real Madrid star missed the opening Club World Cup match as he was admitted to hospital earlier this week Kylian Mbappe was hospitalised earlier this week with an 'acute case' of gastroenteritis, forcing him to miss Real Madrid's opening match in the Club World Cup on Wednesday. He has since been discharged to continue his recovery at his team's training base in America. Gastroenteritis is a very common condition usually caused by bacteria according to the NHS. It's especially common in children but can affect anyone of any age and while it usually clears up on its own, it can sometimes require hospitalisation or professional medical help. Key symptoms indicating this illness include: Sudden, watery diarrhoea Feeling sick Vomiting A mild fever Some people might also experience other issues like a loss of appetite, pain and stomach cramps or aches in their limbs and head. Symptoms will usually arise shortly after becoming infected and may last for a week or more. NHS Inform advises: 'If you experience sudden diarrhoea and vomiting, the best thing to do is stay at home until you're feeling better. There's not always a specific treatment, so you have to let the illness run its course. 'You don't usually need to get medical advice, unless your symptoms don't improve or there's a risk of a more serious problem.' Severe dehydration is a possible consequence of gastroenteritis, and this can be lethal if not treated. Symptoms of severe dehydration include not being able to pee, or only passing small amounts of urine, and persistent dizziness. If you or your child experience severe dehydration symptoms or the following issues with gastroenteritis, the NHS recommends calling 111 and getting medical help: Bloody diarrhoea Vomiting constantly, to the point where you can't keep fluids down A high fever Symptoms don't improve over a few days You have underlying conditions like kidney disease, inflammatory bowel disease or a weak immune system If you do fall ill with gastroenteritis, it's best to stay home and avoid places like work, school and hospitals as it is contagious. People can become ill due to close contact with someone with gastroenteritis, touching contaminated surfaces or objects or eating contaminated food, for example if an ill person doesn't wash their hands before cooking. The NHS noted: 'A person with gastroenteritis is most infectious from when their symptoms start until 48 hours after all their symptoms have passed, although they may also be infectious for a short time before and after this.'
The Independent
21 hours ago
- The Independent
US approves breakthrough HIV jab – but aid cuts mean it may not get to millions in need
US medicines regulator the Food and Drug Administration (FDA) has approved a groundbreaking HIV prevention jab hailed as having the potential to quell the Aids pandemic. But the moment has been overshadowed by the spectre of aid cuts, placing in doubt whether this breakthrough injection – lenacapavir – will get to the people who need it most. Lenacapavir given in a twice-yearly injection stops HIV from replicating, protecting close to 100 per cent of people from developing the virus if they are exposed to it. This approval is one of the last crucial steps to getting the drug, branded Yeztugo, out to patients. Although the FDA's approval only applies to US patients, the World Health Organization (WHO) said it paved the way for its own recommendation of the drug and for approval in other countries. Director of WHO's Global HIV, Hepatitis and STI Programmes, Dr Meg Doherty described it as a 'regulatory milestone' adding: 'We are working with partners and national authorities to ensure lenacapavir reaches people who need it most – quickly, safely and equitably.' Researchers have raised concerns that, amid aid cuts, the jab will be too expensive to be taken up by lower-income countries. Gilead – the drugs company producing lencapavir – did not make public the cost of each dose to global funders but it announced a US price of $28,218 per year for each patient. 'If this game-changing medicine remains unaffordable, it will change nothing,' said Winnie Byanyima, executive director of the United Nations' Aids agency, UNAIDS. She called the approval of lenacapavir a 'breakthrough moment' adding the jab, 'could be the tool we need to bring new infections under control – but only if it is priced affordably and made available to everyone who could benefit. ' UNAIDS has seen research that lenacapavir can be produced for just $40 per person per year, falling to $25 within a year of roll out. It is beyond comprehension how Gilead can justify a price of $28,218.' Dr Andrew Hill, a pharmacology research fellow at the University of Liverpool, worked on the research which found lenacapavir could be provided for as little as $25, including a 30 per cent profit margin. 'Scientifically, it's a great moment that we have a drug which has been judged to be safe and efficacious by a leading regulatory authority in the world,'' he said. 'Public health-wise and in terms of the epidemic, it's tragic because the drug is so expensive that it's not going to get used'. It is also unlikely to be affordable in the UK, he said, despite government promises to end new cases of HIV in England by 2030. A Gilead spokesperson said, 'Yeztugo is priced in line with existing branded PrEP [pre-exposure prophylaxis] options. We are working to make Yeztugo accessible for anyone who needs or wants it and expect to see broad insurance coverage in the US. 'We're taking unprecedented actions with urgency to plan for access to lenacapavir for PrEP globally—particularly in low- and lower-middle-income countries where the need is greatest.' Gilead signed agreements with six pharmaceutical companies in India, Pakistan, Egypt, and the US to allow them to make generic versions of the drug in order to increase supply and drive down the cost of the jab. This will take some time. Gilead also agreed to sell enough doses of the jab to protect at least two million people over three years in lower-income countries. These would be paid for by global funders led by the US President's Emergency Plan for Aids Relief (Pepfar) and the Global Fund to Fight Aids, Tuberculosis and Malaria. However, The Independent reported earlier in the month that these doses are now at risk because of US funding cuts. A significant chunk of the money to fund the doses of lenacapavir was set to come from the US-led global Aids response programme, Pepfar, as well as the Global Fund whose biggest donor was the US. This funding is now uncertain. Figures previously reported by The Independent suggest President Trump's slashing of foreign aid has derailed the projected end of the Aids pandemic and could lead to four million extra deaths by 2030. 'It does feel like this thing that could help us end the epidemic sooner is suddenly receding in the chaos,' said Prof Linda-Gail Bekker, whose trial demonstrated lenacapavir's effectiveness. The aid-funded doses are thought to cost much less than the US list price of almost $30k but still roughly five times more expensive than Dr Hill believes is necessary. And they are in an initial pilot phase, he said: 'We need to get into a different level where we're giving lenacapavir to tens of millions of people'. This is even more important as aid cuts are slashing the HIV prevention budgets of governments across Africa, he said. 'We're in this crazy position where we have a brand new highly effective vaccine-like drug and actually we will probably see the epidemic get worse over the next four years.'
